Agilent Technologies and Ameritox Form Collaboration
News Feb 12, 2013
“By using multiple RapidFire systems Ameritox is streamlining the analysis of small panels of exogenous compounds compared to traditional methods of analysis,” said Can Ozbal, director of Agilent’s RapidFire business.
While Agilent’s RapidFire system has been used extensively in pharmaceutical and biopharmaceutical laboratories, this research collaboration with Ameritox is one of the first for Agilent’s RapidFire team in the field of medication monitoring.
“By working together and sharing moment-by-moment laboratory activity, this research arrangement gives both Ameritox and Agilent a vantage point from which we can continue to discover new uses for our science and technology,” said Jay Zimmerman, chief laboratory officer of Ameritox.
“The marriage of Agilent’s technology and Ameritox’s proprietary science could hold the key to major advancements in the field of medication monitoring,” Zimmerman said.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.READ MORE
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.
In a strategic search, scientists created and screened a library of 45,000 new compounds containing chemical elements of widely used immune system suppressants, and say they found one that may prevent reperfusion injury, a tissue-damaging and common complication of surgery, heart attack and stroke.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019